Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A, Bekiari E, Matthews DR, Tsapas A

Diabetes, obesity & metabolism10 Jun 2018Cited by 110 (Europe PMC)

PMID29756388DOI10.1111/dom.13361PepBankPUB-29756388

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis found that subcutaneous semaglutide 0.5 mg reduced HbA1c versus placebo.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that semaglutide 0.5 mg lowered HbA1c more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change vs placebo, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
HbA1c reduction
1.01%
semaglutide 0.5 mg vs placebo
Source sentences
Summary
Compared with placebo, subcutaneous semaglutide 0.5 and 1 mg reduced HbA1c by 1.01% (95% CI, 0.56-1.47) and 1.38% (1.05-1.70), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638801
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis found that subcutaneous semaglutide 1 mg reduced HbA1c versus placebo.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that semaglutide 1 mg lowered HbA1c more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change vs placebo, 1 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
HbA1c reduction
1.38%
semaglutide 1 mg vs placebo
Source sentences
Summary
Compared with placebo, subcutaneous semaglutide 0.5 and 1 mg reduced HbA1c by 1.01% (95% CI, 0.56-1.47) and 1.38% (1.05-1.70), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638802
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis found that both semaglutide doses had superior glycaemic efficacy compared with other antidiabetic agents.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that both semaglutide doses controlled blood sugar better than other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseGlycaemic efficacy vs other antidiabetic agents
Study
n: not reported in source
Comparator
Other antidiabetic agents (sitagliptin, exenatide, liraglutide, dulaglutide, insulin glargine)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Both doses demonstrated superior glycaemic efficacy compared to other antidiabetic agents, including sitagliptin, exenatide, liraglutide, dulaglutide and insulin glargine.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638803
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis found that semaglutide 1 mg reduced body weight versus placebo.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that semaglutide 1 mg led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight change vs placebo, 1 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mgAs given in this study (human).
Measurements
Mean difference in body weight
−4.11 kg
semaglutide 1 mg vs placebo
Source sentences
Summary
Semaglutide also had a beneficial effect on body weight (mean difference vs placebo -4.11 kg, 95% CI -4.85 to -3.37 for semaglutide 1 mg) and systolic blood pressure.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638804
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis found that semaglutide had a beneficial effect on systolic blood pressure.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that semaglutide lowered systolic blood pressure.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide also had a beneficial effect on body weight (mean difference vs placebo -4.11 kg, 95% CI -4.85 to -3.37 for semaglutide 1 mg) and systolic blood pressure
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638805
06HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis found no increased hypoglycaemia rates with semaglutide.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found no higher rate of low blood sugar with semaglutide.
Peptide
Semaglutide
Outcome
No significant changeHypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
We did not observe increased hypoglycaemia rates with semaglutide
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638806
07HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis found an increased incidence of nausea with semaglutide.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that nausea was more common with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
we noted an increased incidence of nausea, vomiting and diarrhoea.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638807
08HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis found an increased incidence of vomiting with semaglutide.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that vomiting was more common with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseVomiting
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
we noted an increased incidence of nausea, vomiting and diarrhoea.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638808
09HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis found an increased incidence of diarrhoea with semaglutide.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that diarrhoea was more common with semaglutide.
Peptide
Semaglutide
Outcome
IncreaseDiarrhoea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
we noted an increased incidence of nausea, vomiting and diarrhoea.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638809
10HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis found that cases of pancreatitis with semaglutide were infrequent.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found that cases of pancreatitis with semaglutide were rare.
Peptide
Semaglutide
Outcome
Not applicablePancreatitis
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Cases of pancreatitis were infrequent
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638810
11HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis found no significant difference in diabetic retinopathy between semaglutide and placebo.
In plain wordsIn adults with type 2 diabetes, a pooled analysis found no significant difference in diabetic retinopathy between semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeDiabetic retinopathy
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Eye
Studied dose
Dose not stated
Measurements
Odds ratio
1.32 ratio
diabetic retinopathy, semaglutide vs placebo
Source sentences
Summary
the odds ratio for diabetic retinopathy compared with placebo was 1.32 (95% CI, 0.98-1.77).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents.
Summary · context
A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included.
Report a problemFND-2975638811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 2/3NCT06363747

The Medically Reproducing Bariatric Surgery (MRB) II Study

Durham VA Medical Centern = 5024 Jun 2024 to est. 3 Nov 2025

Type 2 Diabetes · Obesity

Trial page ClinicalTrials.govUpdated 7 Feb 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.